Table 5.
Diagnostic accuracy of MTV and ASP towards IR (TG/TL)
| TG/TL 1 | TG/TL 2 | TG/TL 3 | ||||
|---|---|---|---|---|---|---|
| Parameter | Sens. (95%-CI) | Spec. (95%-CI) | Sens. (95%-CI) | Spec. (95%-CI) | Sens. (95%-CI) | Spec. (95%-CI) |
| NPV (95%-CI) | PPV (95%-CI) | NPV (95%-CI) | PPV (95%-CI) | NPV (95%-CI) | PPV (95%-CI) | |
| MTV | 100% (54 to 100%) | 83% (36 to 100%) | 80% (44 to 97%) | 71% (29 to 96%) | 75% (43 to 95%) | 89% (52 to 100%) |
| 100% (48 to 100%) | 86% (42 to 100%) | 71% (29 to 96%) | 80% (44 to 97%) | 73% (39 to 94%) | 90% (55 to 100%) | |
| ASP | 83% (36 to 100%) | 67% (22 to 96%) | 80% (44 to 97%) | 43% (10 to 82%) | 58% (28 to 85%) | 78% (40 to 97%) |
| 80% (28 to 99%) | 71% (29 to 96%) | 60% (15 to 95%) | 67% (35 to 90%) | 58% (28 to 85%) | 78% (40 to 97%) | |
TG/TL treatment group/level, Sens. sensitivity, 95%-CI 95%-confidence interval, spec. Specificity, NPV negative predictive value, PPV positive predictive value, MTV metabolic tumor volume, ASP asphericity